Patents Assigned to STCUBE & CO., INC.
  • Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
    Patent number: 11970534
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 30, 2024
    Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas System
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma
  • Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
    Patent number: 11542331
    Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: January 3, 2023
    Assignee: STCUBE & CO., INC.
    Inventors: Stephen Sunghan Yoo, Ezra Myung Chul Chung, Yong-Sik Bong, Yong-Soo Kim
  • Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
    Patent number: 10875920
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 29, 2020
    Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas System
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma